News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
380,687 Results
Type
Article (18620)
Company Profile (290)
Press Release (361777)
Section
Business (111616)
Career Advice (430)
Deals (21567)
Drug Delivery (53)
Drug Development (61798)
Employer Resources (52)
FDA (9323)
Job Trends (7630)
News (202389)
Policy (16940)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (1252)
Accelerated approval (2)
Adcomms (15)
Allergies (60)
Alliances (28508)
ALS (66)
Alzheimer's disease (1056)
Antibody-drug conjugate (ADC) (82)
Approvals (9320)
Artificial intelligence (142)
Autoimmune disease (10)
Automation (7)
Bankruptcy (196)
Best Places to Work (6783)
BIOSECURE Act (6)
Biosimilars (41)
Biotechnology (238)
Bladder cancer (47)
Brain cancer (19)
Breast cancer (171)
Cancer (1419)
Cardiovascular disease (114)
Career advice (373)
Career pathing (4)
CAR-T (117)
Cell therapy (332)
Cervical cancer (9)
Clinical research (50206)
Collaboration (548)
Compensation (215)
Complete response letters (17)
COVID-19 (1405)
CRISPR (34)
C-suite (144)
Cystic fibrosis (89)
Data (1464)
Denatured (12)
Depression (32)
Diabetes (154)
Diagnostics (3052)
Digital health (7)
Diversity (2)
Diversity, equity & inclusion (18)
Drug discovery (82)
Drug pricing (59)
Drug shortages (16)
Duchenne muscular dystrophy (63)
Earnings (47113)
Editorial (24)
Employer branding (5)
Employer resources (46)
Events (61536)
Executive appointments (426)
FDA (10065)
Featured Employer (35)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (506)
Gene editing (83)
Generative AI (14)
Gene therapy (235)
GLP-1 (422)
Government (1942)
Grass and pollen (3)
Guidances (33)
Healthcare (9831)
Huntington's disease (23)
IgA nephropathy (19)
Immunology and inflammation (75)
Indications (20)
Infectious disease (1482)
Inflammatory bowel disease (115)
Inflation Reduction Act (10)
Influenza (25)
Intellectual property (59)
Interviews (60)
IPO (11458)
IRA (24)
Job creations (1234)
Job search strategy (334)
Kidney cancer (7)
Labor market (6)
Layoffs (222)
Leadership (5)
Legal (2935)
Liver cancer (44)
Lung cancer (197)
Lymphoma (90)
Machine learning (1)
Management (12)
Manufacturing (149)
MASH (50)
Medical device (6221)
Medtech (6223)
Mergers & acquisitions (10479)
Metabolic disorders (431)
Multiple sclerosis (52)
NASH (14)
Neurodegenerative disease (58)
Neuropsychiatric disorders (22)
Neuroscience (1428)
NextGen: Class of 2025 (2948)
Non-profit (1384)
Northern California (1726)
Now hiring (19)
Obesity (232)
Opinion (140)
Ovarian cancer (57)
Pain (55)
Pancreatic cancer (58)
Parkinson's disease (99)
Partnered (7)
Patents (131)
Patient recruitment (66)
Peanut (39)
People (31794)
Pharmaceutical (51)
Pharmacy benefit managers (11)
Phase I (16768)
Phase II (22806)
Phase III (15706)
Pipeline (704)
Podcasts (43)
Policy (54)
Postmarket research (1272)
Preclinical (6821)
Press Release (36)
Prostate cancer (68)
Psychedelics (35)
Radiopharmaceuticals (226)
Rare diseases (299)
Real estate (2114)
Recruiting (19)
Regulatory (13314)
Reports (18)
Research institute (1210)
Resumes & cover letters (56)
Rett syndrome (2)
RNA editing (1)
RSV (21)
Schizophrenia (54)
Series A (101)
Series B (56)
Service/supplier (2)
Sickle cell disease (45)
Southern California (1507)
Special edition (10)
Sponsored (22)
Startups (2243)
State (1)
Stomach cancer (8)
Supply chain (32)
The Weekly (31)
United States (14393)
Vaccines (289)
Venture capitalists (29)
Webinars (8)
Weight loss (141)
Women's health (16)
Worklife (4)
Date
Today (142)
Last 7 days (622)
Last 30 days (2198)
Last 365 days (26568)
2025 (4227)
2024 (27067)
2023 (29975)
2022 (36152)
2021 (38045)
2020 (34015)
2019 (23991)
2018 (17744)
2017 (19641)
2016 (17036)
2015 (20753)
2014 (15137)
2013 (11197)
2012 (11471)
2011 (12022)
2010 (11392)
Location
Africa (285)
Alabama (40)
Alaska (3)
Arizona (86)
Arkansas (7)
Asia (26275)
Australia (5642)
California (3929)
Canada (1430)
China (337)
Colorado (161)
Connecticut (192)
Delaware (87)
Europe (50952)
Florida (531)
Georgia (127)
Idaho (21)
Illinois (257)
India (14)
Indiana (143)
Iowa (1)
Japan (104)
Kansas (64)
Kentucky (8)
Louisiana (7)
Maine (42)
Maryland (517)
Massachusetts (3107)
Michigan (91)
Minnesota (183)
Mississippi (1)
Missouri (41)
Montana (18)
Nebraska (9)
Nevada (40)
New Hampshire (47)
New Jersey (1138)
New Mexico (13)
New York (1090)
North Carolina (656)
North Dakota (5)
Northern California (1726)
Ohio (117)
Oklahoma (8)
Oregon (22)
Pennsylvania (817)
Puerto Rico (3)
Rhode Island (13)
South America (447)
South Carolina (8)
Southern California (1507)
Tennessee (49)
Texas (520)
Utah (84)
Virginia (84)
Washington D.C. (35)
Washington State (408)
West Virginia (2)
Wisconsin (19)
380,687 Results for "antisense therapeutics limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
January 8, 2025
·
4 min read
Business
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics
Secarna Pharmaceuticals GmbH & Co. KG and Orbit Discovery Ltd. today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.
May 28, 2024
·
2 min read
Business
Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
March 20, 2024
·
4 min read
Rare diseases
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential payments due to Stoke.
February 18, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
December 23, 2024
·
6 min read
Press Releases
Antisense and RNAi Therapeutics Market Size to Surge USD 30.03 Bn by 2033: 19.12% CAGR Growth Outlook
August 7, 2024
·
14 min read
Press Releases
U.S. Antisense And RNAi Therapeutics Market Size to Hit USD 17.87 Bn by 2033
June 11, 2024
·
12 min read
Genetown
Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicines
Alloy Therapeutics announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.
June 28, 2023
·
6 min read
Biotech Beach
BOLDEN THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS
Bolden Therapeutics, Inc. today announced the closing of their $1.5M pre-seed convertible note financing.
January 17, 2024
·
2 min read
Press Releases
EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand
July 9, 2024
·
3 min read
1 of 38,069
Next
